ID   ICC16
AC   CVCL_E4KJ
RX   PubMed=31109923;
RX   PubMed=39026794;
CC   Part of: Biliary tract cancer cell line atlas.
DI   NCIt; C35417; Intrahepatic cholangiocarcinoma
DI   ORDO; Orphanet_70567; Cholangiocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 19-12-24; Last updated: 19-12-24; Version: 1
//
RX   PubMed=31109923; DOI=10.1158/2159-8290.CD-19-0182; PMCID=PMC6677584;
RA   Goyal L., Shi L., Liu L.Y., Fece de la Cruz F., Lennerz J.K.,
RA   Raghavan S., Leschiner I., Elagina L., Siravegna G., Ng R.W.S., Vu P.,
RA   Patra K.C., Saha S.K., Uppot R.N., Arellano R.S., Reyes S., Sagara T.,
RA   Otsuki S., Nadres B., Shahzade H.A., Dey-Guha I., Fetter I.J., Baiev I.,
RA   Van Seventer E.E., Murphy J.E., Ferrone C.R., Tanabe K.K., Deshpande V.,
RA   Harding J.J., Yaeger R.D., Kelley R.K., Bardelli A., Iafrate A.J.,
RA   Hahn W.C., Benes C.H., Ting D.T., Hirai H., Getz G., Juric D.,
RA   Zhu A.X.-X., Corcoran R.B., Bardeesy N.M.;
RT   "TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in
RT   patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma.";
RL   Cancer Discov. 9:1064-1079(2019).
//
RX   PubMed=39026794; DOI=10.1101/2024.07.04.601970; PMCID=PMC11257448;
RA   Vijay V., Karisani N., Shi L., Hung Y.-H., Vu P., Kattel P., Kenney L.,
RA   Merritt J., Adil R., Wu Q.-B., Zhen Y.-L., Morris R., Kreuzer J.,
RA   Kathiresan M., Herrera Lopez X.I., Ellis H., Gritti I.G., Lecorgne L.,
RA   Farag I., Popa A., Shen W., Kato H., Xu Q., Balasooriya E.R., Wu M.-J.,
RA   Chaturantabut S., Kelley R.K., Cleary J.M., Lawrence M.S., Root D.E.,
RA   Benes C.H., Deshpande V., Juric D., Sellers W.R., Ferrone C.R., Haas W.,
RA   Vazquez F., Getz G., Bardeesy N.M.;
RT   "Generation of a biliary tract cancer cell line atlas reveals
RT   molecular subtypes and therapeutic targets.";
RL   bioRxiv 2024:07.04.601970-07.04.601970(2024).
//